Details
Stereochemistry | RACEMIC |
Molecular Formula | C19H24N2O.H2O4S |
Molecular Weight | 394.485 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OS(O)(=O)=O.CC(CC(C(N)=O)(C1=CC=CC=C1)C2=CC=CC=C2)N(C)C
InChI
InChIKey=GEKOQGPXZRQQHJ-UHFFFAOYSA-N
InChI=1S/C19H24N2O.H2O4S/c1-15(21(2)3)14-19(18(20)22,16-10-6-4-7-11-16)17-12-8-5-9-13-17;1-5(2,3)4/h4-13,15H,14H2,1-3H3,(H2,20,22);(H2,1,2,3,4)
Aminopentamide is a potent antispasmodic agent. As a cholinergic blocking agent for smooth muscle, its action is similar to atropine. Aminopentamide hydrogen sulfate is marketed under the brand name Centrine indicated in the treatment of acute abdominal visceral spasm, pylorospasm or hypertrophic gastritis and associated nausea, vomiting and/or diarrhea of the dogs and cats. Centrine effectively reduces the tone and amplitude of colonic contractions to a greater degree and for a more extended period than does atropine. Centrine effects a reduction in gastric secretion, a decrease in gastric acidity and a marked decrease in gastric motility. Aminopentamide is a nonselective muscarinic cholinergic .
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094109 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Centrine Approved UseCentrine is indicated in the treatment of acute abdominal visceral spasm, pylorospasm or hypertrophic gastritis and associated nausea, vomiting and/or diarrhea. Launch Date1970 |
PubMed
Title | Date | PubMed |
---|---|---|
The pharmacological activity of DL-alpha, alpha-diphenyl, gamma-dimethylaminovaleramide (centrine). | 1954 Jan |
|
Some aspects of the pharmacology and clinical application of a parasympatholytic agent, aminopentamide. | 1956 Sep 1 |
|
[Broncholytic effect of a new synthetic drugs: aminopentamide]. | 1957 Jun |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.law.cornell.edu/cfr/text/21/522.62
Dogs and cats: Administer by subcutaneous or intramuscular injection every 8 to 12 hours as follows: For animals weighing up to 10 pounds (lbs): 0.1 mg; For animals weighing 11 to 20 lbs: 0.2 mg; For animals weighing 21 to 50 lbs: 0.3 mg; For animals weighing 51 to 100 lbs: 0.4 mg; For animals weighing over 100 lbs: 0.5 mg. Dosage may be gradually increased up to a maximum of five times the suggested dosage. Following parenteral use, dosage may be continued by oral administration of tablets.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13118479
A concentration of 0.00005 mg of Aminopentamide per ml of bath fluid was found to reduce the frequency of guinea pig ureteral contractions and a concentration of 0.005 mg/ml virtually stopped contractions.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29704
Created by
admin on Fri Dec 15 16:08:40 GMT 2023 , Edited by admin on Fri Dec 15 16:08:40 GMT 2023
|
||
|
CFR |
21 CFR 522.62
Created by
admin on Fri Dec 15 16:08:40 GMT 2023 , Edited by admin on Fri Dec 15 16:08:40 GMT 2023
|
||
|
CFR |
21 CFR 522.1222B
Created by
admin on Fri Dec 15 16:08:40 GMT 2023 , Edited by admin on Fri Dec 15 16:08:40 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID7057604
Created by
admin on Fri Dec 15 16:08:40 GMT 2023 , Edited by admin on Fri Dec 15 16:08:40 GMT 2023
|
PRIMARY | |||
|
5897-62-1
Created by
admin on Fri Dec 15 16:08:40 GMT 2023 , Edited by admin on Fri Dec 15 16:08:40 GMT 2023
|
SUPERSEDED | |||
|
176163
Created by
admin on Fri Dec 15 16:08:40 GMT 2023 , Edited by admin on Fri Dec 15 16:08:40 GMT 2023
|
PRIMARY | |||
|
1006396
Created by
admin on Fri Dec 15 16:08:40 GMT 2023 , Edited by admin on Fri Dec 15 16:08:40 GMT 2023
|
PRIMARY | RxNorm | ||
|
20P9NI883O
Created by
admin on Fri Dec 15 16:08:40 GMT 2023 , Edited by admin on Fri Dec 15 16:08:40 GMT 2023
|
PRIMARY | |||
|
20701-77-3
Created by
admin on Fri Dec 15 16:08:40 GMT 2023 , Edited by admin on Fri Dec 15 16:08:40 GMT 2023
|
PRIMARY | |||
|
35144-63-9
Created by
admin on Fri Dec 15 16:08:40 GMT 2023 , Edited by admin on Fri Dec 15 16:08:40 GMT 2023
|
NON-SPECIFIC STOICHIOMETRY | |||
|
C79970
Created by
admin on Fri Dec 15 16:08:40 GMT 2023 , Edited by admin on Fri Dec 15 16:08:40 GMT 2023
|
PRIMARY | |||
|
1025908
Created by
admin on Fri Dec 15 16:08:40 GMT 2023 , Edited by admin on Fri Dec 15 16:08:40 GMT 2023
|
PRIMARY | |||
|
DBSALT002911
Created by
admin on Fri Dec 15 16:08:40 GMT 2023 , Edited by admin on Fri Dec 15 16:08:40 GMT 2023
|
PRIMARY | |||
|
CHEMBL92915
Created by
admin on Fri Dec 15 16:08:40 GMT 2023 , Edited by admin on Fri Dec 15 16:08:40 GMT 2023
|
PRIMARY | |||
|
20P9NI883O
Created by
admin on Fri Dec 15 16:08:40 GMT 2023 , Edited by admin on Fri Dec 15 16:08:40 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD